Endocare Inc

Endocare — Investor Presentation (February 2005)

26 slides from Endocare's investor presentation, Feb 28, 2005

  1. Slide 1: Endocare, Inc. February 2005

    Endocare, Inc. 201 Technology Drive Irvine, California 92618 (949) 450-5400 February 2005

  2. Slide 2: Company Overview

    Company Overview

  3. Slide 3: Mission

    Mission Market - To become the leader in treating cancers and other conditions within various areas of the body through unique, innovative and cost effective cryoablation technologies Corporate - To restore and enhance our reputation and image with the public and with governmental regulatory agencie

  4. Slide 4: Multiple Cryo Applications

    Multiple Cryo Applications

  5. Slide 5: Company Highlights

    Company Highlights Annual procedure growth 35%+ in markets where overall penetration is less than 3% Proven and experienced management team Clinically proven technology in prostate cancer with strong IP positioning and patent protection $400 million growing market in prostate cancer $750 million gro

  6. Slide 6: Endocare Executive Management

    Endocare Executive Management Craig T. Davenport - CEO & Chairman - Chief Executive Officer since December 2003; Chairman since January 2004 - 1994 to 2003 CEO & Managing Partner of The D.W. Group Private investment company - 1985 to 1993 President & COO of Tokos Medical Corporation (NASDAQ) Medical

  7. Slide 7: Endocare Technology Groups

    Endocare Technology Groups Vacuum Technology Erectile Dysfunction Cryoablation Technology Urology Renal Cancer Prostate Cancer Radiology Kidney Tumors Liver Tumors Lung Tumors Bone Pain 7

  8. Slide 8: Current Cryo Systems

    TM Current Cryo Systems CryoCare CryoCare TM

  9. Slide 9: Endocare Technology Advancement

    Endocare Technology Advancement Advancement Advancement Advancement Advancement Cryocare CS (2003) 8 probe Cryosurgical System High Quality Bi-plane U/S Planning System Auto Freeze System Urethral Warming Hook Up In One Box

  10. Slide 10: Prostate Cryo Advancements

    Prostate Cryo Advancements Planning Skill of Surgeon Computer Aided Cryoprobe 3mm Salinger Technique 2.4mm Direct Access Probe Placement Freehand CryoGrid Freezing Manual Operation Auto Freeze Ultrasound Poor Visual Excellent Visual Cryogen Liquid Nitrogen Argon Probe Placement 5 - Star Pattern 6 -

  11. Slide 11: Cryocare CS User Interface

    Cryocare CS (user interface) Cryocare CS (user interface) CryoProbe Technology 11

  12. Slide 12: CryoProbe Technology Features

    CryoProbe Technology Features Multiple probe system Right Angle design CT-compatible Fits under CT Gantry Tumors easily targeted Wide grip handle Features 6 - 2.4 mm Cryoprobes 6 - TemProbes Warming Catheter CryoGrid 12

  13. Slide 13: Market Analysis and Positioning

    Market Analysis and Positioning Urology - Prostate Cancer - Renal Cancer Interventional - Lung, Liver, Bone Radiology & Oncology

  14. Slide 14: Cryoablation Market Positioning

    Cryoablation Market Positioning Cryoablation provides an important tumor/tissue ablation modality with unique physician and patient benefits Broad applications - breast, lung, liver, kidney, bone, prostate Long term proven efficacy (10-year liver and prostate, 5-year kidney) Minimally invasive - goo

  15. Slide 15: Urology - Primary PCa Population

    Urology - Primary PCa Population 2004 Number of Primary Cryotherapy Procedures 5000 Estimated # of All Other Treatments 180000 Source: Health Advances Interviews, Millennium Research Group, CJS Securities and Company estimates. Potential Primary Procedures Distant or Unstaged 20,000 Prostate Cancer

  16. Slide 16: Urology - Salvage PCa Population

    Urology - Salvage PCa Population An estimated 12,000 patients/year experience local recurrence after radiation treatment becoming candidates for cryotherapy; given the current low penetration of cryo in this population, there is significant room for growth. 2004 Estimated # of Salvage Cryotherapy Pr

  17. Slide 17: Urology Cryotherapy Positioning

    Urology Cryotherapy Positioning Primary Cryo Focal Cryo Salvage Cryo Renal Cryo Prostate Cancer Urology Sales Model Direct Sales Force of 18; 4 Regional Managers Growth from the install base of 350 "active" physicians New physician growth of 100 - 150 new physicians per year Sell clinical advantages

  18. Slide 18: Interventional Radiology & Oncology Procedures per Year

    0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 2002 2003 2004 2005 2006 2007 2008 2009 2010 Procedures per Year Kidney Procedures Liver Procedures Bone Procedures Lung Procedures Interventional Radiology & Oncology Procedures per Year - Kidney, Liver, Lung & Bone Pain 60% CAGR (Med

  19. Slide 19: IR & Oncology - PerCryo Positioning

    IR & Oncology - PerCryo Positioning Lung Cryo Bone Cryo Liver Cryo Kidney Cryo PerCryo Sales Model Direct Sales Force of 6; 1 Regional Manager Target RF programs 10+ cases per month Sell clinical advantages of Cryo Place/Provide Cryocare Systems for use Sell Probes to Hospitals - $1,000 ASP for a Pr

  20. Slide 20: Endocare Procedure Growth

    Endocare Procedure Growth 1,546 3,554 2,479 Endocare Direct Market Procedure Growth Reflects all Cryo Procedures Completed 2001-2003 Historical and Projected Procedure Growth 2001-2005E 4,720 6,550 20

  21. Slide 21: 2005 Objectives

    2005 Objectives

  22. Slide 22: Current Outlook & Assessment

    Current Outlook & Assessment · Annual growth in procedures 35%+ in markets where overall penetration is less than 3%. Experienced management team that has lead the Company's turnaround. Clinically proven technology in prostate cancer with strong IP positioning and patent protection. $400 million+ gr

  23. Slide 23: Q1 2005 - Objectives & Outlook

    Q1 2005 - Objectives & Outlook Financial Complete capital fund raising Corporate Finally resolve SEC investigations Continue AMEX listing application process Procedures Continue historical, accelerated procedure growth of +35% Physicians Add 30+ new physicians in Q1 Marketing - National news coverag

  24. Slide 24: Q2 2005 - Objectives & Outlook

    Q2 2005 - Objectives & Outlook Financial Further reductions in cash burn Continue accelerated procedural growth Gross Margin improvement continues Corporate Complete AMEX listing application Resolve DOJ investigation Procedures - Continue historical, accelerated procedure growth of +35% Physicians A

  25. Slide 25: 2H 2005 - Objectives & Outlook

    Financial - Position company for break-even early in 2006 Corporate Create interest for several research analysts to pick up coverage of the Company Gain AMEX Listing by 4th Qtr Procedures - Continue our historical, accelerated procedure growth of +35% Physicians Add 60+ new physicians for a total o

  26. Slide 26: Endocare 2005 Outlook Summary

    Unique clinically proven technology for tissue and tumor ablation with broad market potential and strong IP Rapid procedural growth in large expanding markets Accelerating market acceptance among physicians, academics, patients and payers Regulatory issues and problems should be fully resolved early

Endocare — Investor Presentation (February 2005) on 6ix